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Abstract
A MULTIFACETED APPROACH IDENTIFIES ERBB2 AND ERBB3 PROTEINS AND
MICRORNA-125B AS KEY CONTRIBUTORS TO PROSTATE CANCER PROGRESSION
by
Danielle E. Weaver, BS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Bioinformatics at Virginia Commonwealth University.
Virginia Commonwealth University, 2012

Prostate cancer is the most common cancer affecting men today. Therefore, there is a
strong need for accurate biomarkers and successful therapeutic treatments. A novel approach
combining a computationally built protein-protein interaction network of proven microRNA
protein targets with high throughput proteomics identified ErbB2 and ErbB3 as key proteins in
prostate cancer. These results coupled with microRNA array screening of an androgenindependent prostate cancer progression model, substantiated by single microRNA analysis,
suggested miR125b as a key tumor suppressor contributing to prostate cancer progression.
miR125b expression was shown to be substantially increased in the non-tumorigenic P69 cell
line compared to its highly tumorigenic, metastatic M12 variant. Luciferase reporter gene assays
including the entire 3’UTR of either ErbB2 or ErbB3 revealed a 2.8- and 2.4-fold decrease
(respectively) compared to control vector. Thus, this combinatorial approach has suggested an
additional microRNA and its target involved in prostate tumor progression.

Chapter 1: Introduction
The Prostate Organ:
The prostate organ is part of the male reproductive system and is located in front of the
rectum and under the bladder. The prostate is an exocrine gland that produces two-thirds of the
volume of seminal fluid. This fluid is alkaline in nature to help neutralize the acidity of the
vagina, allowing sperm to survive longer and protect genetic material. During ejaculation, the
prostate’s smooth muscles contract helping to expel the seminal fluid, carrying the sperm
through the penis as semen.
A healthy and mature prostate is roughly the size of a walnut and surrounds the urethra,
the tube that passes urine from the bladder to the penis. In half of all men, around the age of fifty,
the prostate begins to enlarge to abnormal size due to male hormones (androgens). This
enlarging of the prostate can be classified as benign growth or malignant. Benign cases are often
referred to as benign prostatic hyperplasia (BPH), where the prostate becomes enlarged and
presses on the urethra slowing or stopping the flow of urine. This is non-cancerous and the
overgrowth of these cells does not result in invasion into other tissue. In malignant cases, the
cells can invade or damage nearby tissue leading to cancer of the prostate gland.
Incidence of Prostate Cancer in the United States:
Prostate Cancer is the most common cancer affecting men in the United States today with
over 2.5 million identified manifestations 1. It is the second leading cause of cancer related
deaths in American men 2. In 2012, it is estimated that 241,740 new cases of prostate cancer will
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be diagnosed and 28,170 men will succumb to the disease 1. Essentially one in every six males in
the U.S. will develop prostate cancer in their lifetime.
The development of prostate cancer has been linked to age, race, and family history 2.
Age is an important factor influencing the likelihood of contracting the disease. Nearly 65% of
men diagnosed with prostate cancer are of age 65 or older. Figure 1-1 depicts the incidence of
prostate cancer in all males according to age at the time of diagnosis per 100,000 men based on
the data obtained from the National Cancer Institute Surveillance Epidemiology and End Results
database3. Therefore, a man’s risk of developing prostate cancer increases as he ages and peaks
between the ages of 70-74. It is remarkably uncommon for men to be diagnosed prior to the age
of 50.
In addition to age, a man’s race or ethnicity has a major influence on the probability of
contracting the disease. On average, 156 out of every 100,000 males in the United States will be
diagnosed with prostate cancer 3. White males have a lower than average overall incidence of
prostate cancer of 149.5 out of every 100,000 males. African-American males have the highest
overall incidence rate of 233.8 out of every 100,000. Figure 1-2 depicts the incidence of prostate
cancer broken down by both age at the time of diagnosis and race/ethnicity per every 100,000
males in the population 4. African-American men are three times more likely to die from prostate
cancer than their white counterparts, while Asian-American men are the least likely race to
contract the disease 2.
Family history, as in most diseases, also plays a role in a man’s risk for developing
prostate cancer. Men who have a single relative who was diagnosed with prostate cancer are
twice as likely to develop the disease, while men with two or more relatives who have the
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Figure 1-1: Variation in the incidence of prostate cancer based on age of patient.
Age is an important factor influencing the likelihood of contracting the disease. Nearly 65% of
men diagnosed with prostate cancer are of age 65 or older 2. Men are most commonly diagnosed
around age 70 and very infrequently diagnosed prior to the age of 50. Incidence is based on
100,000 men.
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Figure 1-1: Variation in the incidence of prostate cancer based on age of patient.
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Figure 1-2: Variation in incidence of prostate cancer based on age and race/ethnicity.
African-American males are much more likely to contract prostate cancer than any other race in
the United States. Asian-American males are least likely to be diagnosed with the disease. All
males are most commonly diagnosed around age 70. Incidence is based on 100,000 men.
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disease are four times as likely2. The men who are most susceptible are those whose family
members were diagnosed prior to the age of 50 due to the rarity of the disease at younger ages.
Prostate Cancer Detection:
In 1986 the U.S. Food and Drug Administration (FDA) approved the prostate specific
antigen (PSA) test for monitoring disease status in prostate cancer patients 5. In 1994 the FDA
approved the PSA test for early detection of prostate cancer in men of age 50 or older. PSA is a
protein produced by cells in the prostate gland 6. The PSA test measures the level of the PSA
protein in the blood to determine those at risk for developing the disease. Low levels of PSA are
normal while increased levels of PSA can be present for benign or malignant conditions.
However, PSA levels alone cannot effectively diagnose prostate cancer, therefore a digital rectal
exam (DRE) is used in combination with PSA monitoring for diagnosing the disease. A multiinstitute funded clinical trial comparing the PSA test and DRE as screening tools determined that
PSA testing alone identified 75% of tumors while DRE only identified 55%7. The combination
of both the PSA test and DRE test identified the most tumors, 78%.
Figure 1-3 depicts the trend in prostate cancer detection from 1975 to 2008 according to
the data provided from the National Cancer Institute Surveillance Epidemiology and End Results
database. In 1975, 94 out of every 100,000 men were diagnosed with prostate cancer 3.
Beginning in 1987, exponential growth was seen in the incidence rate, peaking in 1992 with 237
out of every 100,000 men being diagnosed. As of 2008, 153 out of every 100,000 men were
diagnosed. Several schools of thought have emerged as to the enormous spike in prostate cancer
detection in the late 80’s early 90’s, with the introduction of PSA testing being on the forefront.
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Figure 1-3: Prostate cancer incidence trend 1975-2008.
In 1975, 94 out of every 100,000 men were being diagnosed with prostate cancer. Beginning in
1987, exponential growth was seen in the incidence rate, peaking in 1992 with 237 out of every
100,000 men being diagnosed. As of 2008, 153 out of every 100,000 men are being diagnosed 3.
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Figure 1-3: Prostate cancer incidence trend 1975-2008.
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Increased awareness of the disease as well as the fact that the average life span of Americans has
increased are also contributing to the increase in detection of prostate cancer.
The genetics of prostate tumorigenesis:
As stated before, genetics and family history can play a major role in the development of
prostate cancer. Prostate cancer has a heterogeneous nature and is highly complex therefore
mutations in a multitude of genes can play a role in tumor progression 8. Consequently, scientists
are actively trying to identify genes, RNAs and proteins that can be associated with tumor
progression and serve potentially as biomarkers. A biomarker is a biological molecule that can
be quantified and is associated with normal or better yet abnormal forms of a disease. Table 1-1
shows a list of genes and their associated functions from a recent study identifying differentiallyregulated genes from androgen-dependent to androgen-independent tumor progression 8. Only
the most differentially expressed genes were selected; however, these are unquestionably not the
only genes associated with prostate tumorigenesis. Genes are thought to influence tumor
progression by the accumulation of point mutations that inadvertently inactivate the gene or by
dysregulation via several routes.
Tumor reoccurrence emerges in 15-30% of prostate cancer patients generally within 5
years of initial treatment 2. These patients are then treated with androgen withdraw (AW) therapy
and 70-80% of patients respond positively to this treatment temporarily. However, eventually the
tumors progress to an androgen-independent, a highly metastatic and aggressive form 9. In a
normal prostate cell and androgen-dependent prostate tumors, testosterone will bind to the
androgen receptor triggering the production of androgen transcripts which stimulates cell growth.
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Table 1-1: Differentially expressed genes from androgen-dependent to androgenindependent prostate tumor progression.
Gene Symbol Gene Name
IGF1
Insulin-like growth
factor 1
EGFR/ERBB Epidermal growth
factor receptor
TM4SF1
Transmembrane 4
L six family
member 1
WT1
Wilms tumor 1
PAGE-1

RAB27B

SOX4

Function
Involved in mediating growth and
development
Influences cell proliferation

Plays a role in regulation of cell
development, activation, growth
and motility.
Plays essential role in normal
development of urogenital system
P antigen family
Expressed in a variety of tumors
member 1
but not normal tissue. Function
currently unknown
RAS related
Member of the RAS oncogene
protein 27 B
family. Involved in vesicular
fusion and trafficking
SRY- sex
Regulates embryonic
determining region development. May function in
Y
apoptosis as well as tumorigenesis
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Chromosome location
12q23.2
7p12
3q21-q25

11p13
Xp11.23

18q21.2

6p22.3

A study has shown that in cases of androgen-independent tumorigenesis, 50% of the tumors had
point mutations in the androgen receptor gene. Scientists are currently unsure of how androgen
receptors still promote cell growth in the absence of testosterone, but the point mutations may
play a role in this phenomenon.
Fairly recently small non-coding RNAs have been discovered to influence gene
expression by either inhibiting translation or signaling the transcribed genetic message
(messengerRNA, mRNA) for degradation. One class of responsible small RNAs are known as
microRNAs (miRNAs, miRs).
The discovery of miRNAs and their role in oncogenesis:
MicroRNAs are small non-coding RNAs that are 19-25 (nt) in length 10. They have the
ability to post-transcriptionally regulate gene function by inhibiting translation or marking an
mRNA for degradation. miRNAs have been shown to influence a variety of biological processes
such as cell cycle regulation, differentiation, development, metabolism and aging 10. miRNAs
were discovered in 1993 in C. elegan development10. They are highly conserved among
organisms that are very distantly related such as invertebrates, vertebrates and plants. The
miRBase database, a database of published miRNAs with annotations, listed 18,226 identified
miRNAs from an assortment of organisms as of November 2011 11.
miRNAs presumably play a role in cancer due to their natural influence on cell cycle
regulation (cell proliferation and apoptosis), differentiation, development and other related
biological processes 12, 13. miRNAs are very frequently located in cancer-related genomic regions
such as minimal regions of amplification, loss of heterozygosity, fragile sites, and common break
point regions on or near oncogenes or tumor suppressor genes. miRNAs function as either
12

oncogenes or tumor suppressors. Oncogenes have been shown to be consistently up-regulated in
tumor verses normal tissue whereas tumor suppressors are down-regulated in tumor versus
normal tissue 10, 12. It also has been show that in some instances, a miRNA may act as a tumor
suppressor in one setting and an oncogene in another 12. Studies have shown that in some
cancers, a global deregulation of miRNAs has been found. This implicates that miRNAs
generally target genes associated with biological processes that are critical for development or
progression of the disease.
MicroRNA biogenesis and mRNA targeting:
miRNAs have been located in the genome in both introns and exons of coding proteins as
well as intergenic regions 12. It is quite common for them to be found polycistronically, clustered
in groups of 2-7 miRNAs as a single transcript controlled by a common regulator, or
monocistronically 12, 14. The first step of miRNA biogenesis begins in the nucleus where the
precursor is transcribed by RNA polymerase II, adding a 5’ cap and a 3’ poly-A tail (Figure 14)10, 12-14. This pri-miRNA is then cleaved into a 70-100 nt hairpin shaped fragment by a
ribonuclease II called Drosha and the double-stranded DNA binding protein DGCR8. The new
fragment is referred to as pre-miRNA. After the hairpin structure is formed, the pre-miRNA is
exported out into the cytoplasm by means of the nuclear export factor exportin. The pre-miRNA
is then processed into a 19-25 nt miRNA duplex via association with the ribonuclease III Dicer.
The miRNA is then incorporated into the RNA-induced silencing complex (RISC). The miRNA
is now mature and is guided toward its intended mRNA target.
miRNAs target genes via complementarity between the miRNA sequence (”seed” region,
bases 2-7 of the miRNA from the 5’ end) and the 3’UTR sequence of the mRNA transcript 12, 14.
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Figure 1-4: microRNA Biogenesis
1. Within the nucleus, the precursor is transcribed by RNA polymerase II and the 5’cap and
3’poly-A tail is added.
2. Also within the nucleus, the pri-miRNA is cleaved into a 70-100 nt hairpin shaped
fragment known as pre-miRNA by Drosha.
3. The pre-miRNA is exported out of the nucleus into the cytoplasm by Exportin.
4. Now in the cytoplasm, the pre-miRNA is processed into a 19-25 nt miRNA duplex by
Dicer.
5. The miRNA duplex is incorporated into RISC and one strand selected as the mature
miRNA and is now prepared to locate its intended target.
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Figure 1-4: Steps in microRNA Biogenesis
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Recently it has been shown that in some cases, a miRNA’s seed sequence complementarity will
correspond to the 5’UTR of an mRNA transcript or potentially, association with any portion of
the target mRNA is sufficient for translational repression 15. Perfect or near perfect binding
complementarity of the miRNA seed region to the target gene leads to mRNA degradation
through the RNA-mediated degradation pathway. Imperfect complementarity is thought to lead
to translational repression 12 at some step down stream of initiation but the mechanism for this
effect remains to be validated 15. It is estimated that over 30% of protein coding genes are
regulated by miRNAs 12. This along with the fact that the seed region of most miRNAs is around
6 nt in length, it is suggested that miRNAs can regulate multiple protein-coding genes.
The Oncogenic Potential of miR17-3p and miR125b when differentially expressed:
The gene that encodes for the miR17-3p (miR17*) mature miRNA is located on
chromosome 13 in a polycistronic cluster known as the miR-17-92 cluster 16. The cluster is
transcribed into a primary transcript that encodes six miRNAs 17. These include miR17 (miR175p and miR17-3p mature miRNAs), miR18a, miR19a, miR20a, miR19b-1 and miR92-1. The
cluster has been shown to be activated by the c-MYC transcription factor 18. In human solid
tumors, miR17-5p was shown to be up-regulated in breast, colon, lung, pancreas and prostate
cancers 19. In the same study, miR20a was shown to be up-regulated in colon, pancreas and
prostate cancers. miR17-3p has been shown to be down-regulated in prostate cancer when
comparing benign versus malignant tumor samples collected via laser capture microdissection 19.
A gene that encodes for the miR125b is located in two separate locations within the
human genome, chromosomes 11 and 21 (precursor miR125b_1 and miR125b_2 respectively)
both found monocistronically. When fully processed both precursors produce mature miR125b

16

molecule. miR125b has been shown to be differentially dysregulated in a multitude of human
cancers: down-regulated in breast 20, 21, ovarian 22, squamous cell carcinoma 23, but up-regulated
in neuroblastoma 24, stomach 25, colon 21, and bladder 26. According to miRecords, an online
database of miRNA-target interactions, miR125b has been experimentally proven to target 52
proteins as of November 201027.
Prostate Cancer Cell Models:
There are three classical sets of tissue culture cell lines used by researchers to help better
investigate prostate cancer overall and prostate cancer tumor progression. The LNCaP, DU-145,
and the P-C3 cell lines 28. The DU-145 cell line was the first prostate cancer cell line to be
established and was derived from a metastatic tumor excised from the brain of a 69 year old
white male with prostate cancer. These cells fail to express the androgen receptor gene/protein
(AR), therefore classifying them as androgen-independent.
The LNCaP cell line was derived from a biopsy of a lymph node metastasis from a 50
year old white male with prostate cancer 28. Although there are 60+ LNCaP sublines, the parental
cell line expresses both the AR gene and protein, classifying them as androgen-dependent. This
is currently the most popular cell line used by researchers.
The PC-3 cell line was derived from a lumbar vertebra metastasis from a 62 year old
white male with prostate cancer 28. The parental cell line fails to express the AR gene/protein,
classifying them as androgen-independent. There are 11 sublines that have been derived from the
PC-3 parental cell line, some of which are androgen-dependent.
The model system used in our lab is a genetically related androgen-independent cell line
derived from a non-neoplastic prostate epithelial cell from a 63 year old African American male
17

29

. These cells were immortalized with the SV40 Large T Antigen gene and referred to as P69.

The P69 cell line is non-metastatic, and weakly tumorigenic. The M12 cell line was derived from
the parental P69 line by interperitonal injection into male, athymic nude mice. In some cases
after sufficient time (months) tumors developed. Tumors were collected, cells dispersed, and
reinjected into mice as before 29. After three rounds of injections the resulting M12 cell line was
derived. The karyotype for the M12 subline shows an unequal translocation of chromosome
16:19, resulting in the loss of most of one copy of chromosome 19. Interestingly, an
independently derived second cell line showed a similar chromosomal rearrangement as the M12
cell line suggesting this chromosomal rearrangement can be independently duplicated during
tumorigenesis. The M12 cell line is highly metastatic and tumorigenic when injected
orthtopically into male, athymic nude mice. The F6 subline was derived from the M12 cell line
by restoration of the lost copy of chromosome 19 via micro-cell fusion techniques 30. The
restoration of the second copy of chromosome19 resulted in a poorly tumorigenic, nonmetastatic phenotype for the F6 cell line, like the P69 predecessor. Altogether, these cell lines
generate a useful model system for studying factors that contribute to the progression from a
normal epithelial cell line to a highly metastatic, tumorigenic versus weakly variant, originally
derived from a common cellular background.
Previously, it was found that the P69 cell line had a relatively high abundance of the
human miRNA 17-3p. The M12 subline exhibits a two-fold decrease in the expression of miR173p compared to the parental P69 cell line. A M12 subline with restored expression (approximate
an additional 3-fold) of miR17-3p (M12+miR17-3p) was derived 31. A variety of experiments
suggests that miR17-3p acts as tumor suppressor in vitro and in vivo 31.
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The ErbB Protein family and it’s role in oncogenesis:
The the ErbB family or epidermal growth factor receptor (EGFR) family is comprised of
four protein homologs: EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/HER3 and ErbB4/HER4
32

. All of these members are type 1 transmembrane tyrosine kinase receptors and contain a

extracellular ligand-binding domain, a single transmembrane-spanning region and a cytoplasmic
protein tyrosine kinase domain attached to a C-terminal tail 2. Signaling by the ErbB family has
been shown to regulate several cellular activities including cell division, migration, adhesion,
differentiation and apoptosis.
The ErbB receptors are activated by mesenchymal ligands to include heregulines,
neureguins and other EGF-like ligands, each with an EGF-like domain for binding specificity 32.
When a ligand binds to the extracellular ligand-binding domain, it activates the ErbB receptor
allowing dimerization to another ligand-bound ErbB receptor2. This is true for all members
except for ErbB2 which is constitutively available for dimerization, thus not requiring ligand
binding for activation 32.
The ErbB receptors can either homo or hetero dimerize and this action is essential to
their function and signaling activity 2. Homodimers only propagate a weak signal compared to
heterodimers. ErbB2 has been shown to be the primary heterodimerization partner for all other
ErbB members 32 and ErbB2 heterodimers are the most potent 2. ErbB3 is unable to
homodimerize due to insufficient kinase signaling but ErbB2-ErbB3 heterodimers are the most
mitogenic of all of the other heterodimer combinations. ErbB4 expression has been shown to be
lost in prostate cancer 33.
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Once dimerization has occurred, the kinase domain is activated and autophosphorylation
of the tyrosine residues within the cytoplasmic tail follows 2. The signaling cascade is initiated
when docking of an adapter protein occurs at the phosphotyrosine residues. Each of the ErbB
receptors has a unique pattern of tyrosine residues phosphorylated in the C-terminal tail,
specifying which adapter proteins may bind and in turn, which signaling pathways are initiated
32

. ErbB3 comprises six binding sites for the p58 regulatory subunit of the PI3Kprotein

(phosphoinositide 3-kinase), enabling direct activation of the PI3K signaling pathway 2, 32. All
members of the ErbB family have binding sites for activators of the MAPK (mitogen activated
protein kinase) pathway as well.
Activation of the PI3K pathway involves initial EGFR dimer binding with a PI3K adapter
protein, activating downstream AKT which in turn inhibits the FOXO transcription factors,
mediators of apoptosis 34. Activation of the MAPK pathway involves initial binding with a
MAPK adapter protein, activating downstream RAS, RAF and MEK which activates
downstream MAPK, activating the ELK transcription factor which promotes transcription and
cell growth. Gioeli et al measured 82 primary and metastatic prostate tumor samples and showed
increasing MAPK activation correlated with increasing Gleason score and tumor stage 35. These
are only two examples of major signaling pathways activated by the EGFR family.
Three main causes of the ErbBs being involved in oncogenesis have been described: 1)
increased receptor expression and/or gene amplification, 2) increased ligand expression, and 3)
mutations causing constitutive activation of the receptor 2. Abnormal activity has been linked
more to the increased expression of the ligand than mutations in the receptor. ErbB2
overexpression has been associated with metastsis to the bone in both breast and prostate cancer
36

. Overexpression of the ErbB2 and ErbB3 heterodimer has been associated with increased
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tumor growth in breast cancer via the PI3K pathway and is thought to promote the metastatic
potential of the disease 37. Chen et al performed a study using prostate cancer samples that were
both androgen –dependent and –independent, and concluded that there was a statistically
significant increase in ErbB3 expression from androgen –dependent to –independent tumor
samples 38. These findings attest to a significant role for ErbB2 and ErbB3 in prostate
tumorgenesis.
Inhibitors of the ErbB protein family have been developed and are now used clinically to
treat breast cancer resulting in decreased ErbB2 activity 2. However, no inhibitor developed
against ErbB2 has been effective in clinical trials against prostate cancer. Thus far, inhibitors of
ErbB3 have only been mildly considered, since ErbB2 was thought to be the key player in cancer
development. Table 1-2 lists ErbB family members with miRNAs proven to target the ErbBs,
and cancer in which the interactions have been identified 27. Knowing that miRNAs function as
molecules that either inhibit translation or initiate degredation of their target mRNA, they are
interesting as potential biomarkers of the disease or as a possible alternative to drug therapy 39.
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Table 1-2: ErbB family members expressed in cancer with proven miRNA interactions.
Protein target

Proven miRNA

Cancer

ErbB1

hsa-miR-7

Lung, Breast, Glioblastoma

ErbB2

hsa-miR-125a

Breast

hsa-miR-125b

Breast

hsa-miR-331-3p

Prostate

hsa-miR-548d-3p

Cervical

hsa-miR-559

Cervical

hsa-miR-125a

Breast

hsa-miR-125b

Breast

hsa-miR-205

Breast

ErbB3
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Objectives:
Interest in miRNAs has increased over the last years due to their potential as both
biomarkers of disease as well as alternatives to drug therapy. Identification of miRNA targets as
well as their contribution to the development of disease has moved to the forefront of cancer
research. Traditionally used gene arrays evaluate levels of gene expression and are unable to
capture the true nature of protein expression due to post-transcriptional regulation via miRNAs.
Furthermore, strictly computational approaches have generated only minor success in identifying
crucial miRNA targets due to the many possible conformations of miRNA/target coupling.
Our objective is to take a novel approach. Here, a high throughput proteomics method
combined with a computationally derived network is used to identify key proteins driving
prostate cancer progression. This approach enables the evaluation of gene expression levels posttranscriptionally in cancer cell lines with key protein node predictions to identify potential
miRNA interactions. This analysis coupled with screening of the miRnome (miRNA
transcriptome) should enhance the identification of relevant miRNAs dysregulated in prostate
cancer which contribute to tumor progression. Additional experiments such as single miR
analysis in model prostate cancer cell lines compared to human tumors will further validate the
conclusions from this multifaceted approach.
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Chapter 2: A Proteomics Approach to identifying Key Proteins dysregulated in Prostate
Cancer.
Proteomics and RPMA Technology:
Traditionally, gene arrays have been used to try to predict genes involved in prostate
cancer development as well as identify stages of tumor progression 40. Yet the mechanism behind
using gene arrays is to reverse transcribe mRNA into cDNA. Therefore gene expression arrays
measure mRNA levels present prior to translation. Since miRNAs regulate levels of gene
products driving translation, measuring the actual level of protein products should be a more
accurate method of measuring a gene/protein’s activity and potential influence in the cell.
Two major types of protein arrays are in use: Forward phase protein microarrays and
Reverse Phase Protein Microarrays (RPMA) 41. Generally, in forward phase protein arrays, the
antibody(s) of the protein(s) of interest are spotted on to a glass or silica chip used as a bait
molecule, and the chip is incubated with the protein lysate of interest 42. Using this method, only
one type of sample condition can be measured at a time. Conversely, in RPMAs, the cellular
lysate is spotted onto the chip in a series of dilutions and the chip is incubated with the antibody
to the protein of interest 43. This miniature dilution curve is designed to insure accurate
quantification and to describe the overall dynamic range of protein detection. This method allows
for multiple samples to be spotted on the same chip, but requiring one slide for each antibody
analyzed. Overall, both methods produce a high-throughput system for measuring expression
levels of hundreds of proteins across multiple sample conditions.
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Compared to conventional western blotting methods to measure protein expression,
protein microarrays are undoubtedly more efficient considering sample size and time
consumption 44. Western blots use on average around 30ug of protein lysate per sample,
depending on how abundant the protein of interest is in the specific cell or tissue-type. Protein
microarrays can use picograms to femtograms of protein lysate, using only 200 cells total to print
one array slide. Anywhere from 5,000 to 20,000 total cells is sufficient to measure protein
expression across 100 different proteins of interest.
Tissue Culture Methods:
The ‘stock’ media used for P69 and M12 cell lines includes: RPMI 1640 media with Lglutamine from Sigma-Aldrich, 5% fetal bovine serum, ITS (5µg/ml insulin ‘I’, 5µg/ml
transferrin ‘T’ and 5ng/ml selenium ‘S’) from Collaborative Research in Bedford, MA and
0.05mg/ml gentamycin to prevent bacterial growth contamination. The M12+miR-17-3p cell line
contains a stably integrated plasmid and requires puromycin (100µg/µl) in addition to the ‘stock’
media for selection.
All cell types were grown at 37◦C in 250ml T75 flasks and were split when confluent.
Cells were harvested from the flask via scraping over ice and using cold 1xPBS. Cells were
pelleted at 1000 rpm in a 15ml conical tube, re-suspended in 1xPBS and pelleted a second time
at 5000 rpm in a 1.5ml eppendorf tube. The cell pellets were flash frozen using liquid nitrogen
and stored at -80◦C.
For the purpose of this experiment, 1 cell pellet was made from each flask and 3
consecutive passages (denoted as ‘T’ numbers) of each cell line were harvested. The cell pellets
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were then sent on dry ice to Dr. Emanuel Petricoin III’s lab at George Mason University’s Center
for Applied Proteomics and Molecular Medicine.
Reverse Phase Protein Microarray performed at George Mason University:
The cells were lysed prior to spotting in buffer containing 9M urea, 4% 3-[(3chlamidopropyl) dimethylammonio]-1-propanesulfonate, 2% pH 8.0-10.5 Pharmalyte, and
65mM DTT. Each cell pellet lysate was spotted in a miniature serial dilution curve (neat, 1:2,
1:4, 1:8, 1:16 and buffer) onto a glass nitrocellulose-coated slide. The RPMA protocol as
previously described was followed 45. Overall, antibodies for 111 different proteins were
incubated with our various cell lysates to follow protein expression in our prostate cancer
progression model. Many of the antibodies were monoclonals’ raised against specific
phosphorylated residues of the host antigen; thus, used to measure differences in activating
various signaling pathways deemed important in cancer. After verification of their internal
standards and normalization, the Petricoin lab returned the proteomics results for statistical
analysis.
Statistical Analysis of the RPMA data:
Microsoft Excel was used to perform a two-sample equal variance T-Test to compare the
protein expression data across the different cell lines provided. A strict probability value (pvalue) of p <= 0.001 was used to correct for variation among multiple samples and to identify
truly significant changes. Those with significant changes were converted into fold changes by
dividing the average expression of the protein in one cell line by the average expression of the
protein in the comparison cell line. Figure 2-1 depicts the overall process of the statistical
analysis using protein ErbB2 as an example.
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Figure 2-1: Overview of the Statistical Analysis of the RPMA data.
A T-Test was performed to compare the protein expression data across the different cell lines
provided. A p-value of p <= 0.001 was used to correct for multiple samples and to identify truly
significant changes. Those with significant changes were converted into fold changes by dividing
the average expression of the protein in one cell line by the average expression of the protein in
the comparison cell line.
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Figure 2-1: Overview of the Statistical Analysis of the RPMA data.

P69
ErbB3
T23- 6173.37
T24- 7186.79
T25- 8192.71

M12
ErbB3
T14- 15630.82
T16- 14647.13
T17- 15382.72

T-Test:
0.0002512199
Significant?
p <= 0.001

P69
ErbB3 Avg:
7184.29

M12
ErbB3 Avg:
15220.22

Fold change:
P69 -> M12
2X ↑
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RPMA Findings:
Table 2-1 is an overview of proteins shown to have statistically significant changes in
expression level (p-value <= 0.001) within our prostate cancer progression model as measured
by RPMA. Phosphorylated c-KIT, ErbB3 and ErbB2 were the most interesting of the proteins
changing in our proteomics data, because for the most part they showed significant changes
across multiple cell lines. All three proteins showed an increase in expression from the nontumorigenic P69 cell line to the highly metastatic, tumorigenic M12 subline except there was no
significant change (NS) in the phosphorylation status of ErbB2 (phosphorylated Tyrosine 1248).
Interestingly, a decrease in expression from the M12 cell line to the weakly tumorigenic, nonmetastatic M12+miR-17-3p subline with increased expression of the tumor suppressor miR17-3p
was apparent except for ErbB2.
These results are consistent with a protein that is being dysregulated by increased
expression in the highly metastatic cell line compared to the non-tumorigenic/poorly tumorigenic
variant in our model of disease. Since miR17-3p is dysregulated in the opposite direction in our
progression model, (decreasing from P69 to M12 and then increasing from M12 to M12+miR17-3p), there is a possibility that miR-17-3p may be directly targeting pc-KIT, ErbB3 mRNAs
and possibly ErbB2/pErbB2 due to significant changes in at least one direction. Confirmation of
direct miRNA/target interactions is imperative in theidentification of possible biomarkers as well
as therapeutic options for disease. This hypothesis warrants further testing.
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Table 2-1: Fold changes of proteins with statistically significant expression changes based
on RPMA.
Protein

P69

M12 fold change

M12

*pc-KIT

1.7x107X ↑

1.7x107X ↓

ErbB3

2X ↑

1.3X ↓

ErbB2

1.7X ↑

NS

*pErbB2

NS

1.6X ↓

*pERK

5.1X ↓

NS

*pJak1

NS

1.9X ↓

NS- No significant change
↑ Increase in expression
↓ Decrease in expression
*p = antibody used specific to a phosphorylated residue
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M12+miR-17-3p fold change

Chapeter 3: A Networks Approach to Identifying Important miRNA Regulated Proteins in
Prostate Cancer
Networks Biology:
The human body, organs, cells are all very complex systems that require intricate
coordination and proper execution of a remarkable number of biological processes in order to
perform properly 46. Thus far, 5 main types of biological networks have been characterized to
help better understand these biological processes and to observe how the smaller pieces create
the whole. These networks include transcription factor-binding, phosphorylation, metabolic,
genetic, and protein-protein interaction. Focusing on protein-protein interaction networks, the
proteins are considered nodes, and interactions between the nodes are represented as edges. The
interaction of proteins with other proteins in the cell plays a key role in most biological processes
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. The evaluation and identification of all protein-protein interactions within the cell is thought

to be the key to uncovering how cells function on a large-scale, under normal and disease
conditions.
Building a protein-protein interation network of proven targets of miRNAs shown to be
dysregulated in the Prostate:
Figure 3-1 depicts the process of building the protein-protein interaction network
of proven targets of miRNAs dysregulated in the prostate. A list of 111 dysregulated miRNAs,
associated with the development of prostate cancer was obtained from the miR2Disease online
resource 48. The database was interrogated using the included html search function using the
query term “prostate carcinoma”. Causal and unspecified relationships were included. A PERL
script was written to extract each miRNAs expression pattern and literature reference.
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Figure 3-1: Overview of building a protein-protein interaction network of proven targets of
miRNAs dysregulated in the prostate.
miRNAs dysregulated in the prostate were obtained from the miR2Disease database 48.
Experimentally proven miRNA/target interactions were obtained from joining the information in
the Tarbase and miRecords repositories 27, 49. Prostate transcriptome profiles were obtained from
Unigene to determine transcripts expressed in the prostate 50. Agilent and Cytoscape were used in
conjunction to build the protein-protein interaction networks. The network properties were
calculated using CentiScaPe 51-53 .
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Figure 3-1: Overview of building a protein-protein interaction network of proven targets of
miRNAs dysregulated in the prostate.

Determined miRNAs involved in Prostate Cancer

Find Proven Targets

Build protein-protein interaction network

Calculate
Network
Properties

Pathway
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A table of all known miRNA/gene interactions was assembled by combining the
information in Tarbase and miRecords, repositories of experimentally supported miRNA target
interactions that were downloaded in May of 201127, 49. A PERL script was written to compile the
data extracted from both repositories to create a single non-redundant list. Using the
miR2Disease list of miRNAs dysregulated in the prostate, a comprehensive list of validated
targets associated with these miRNAs was created 48.
Transcriptome profiles for the prostate gland were obtained from the Unigene database 50.
A prostate specific protein-protein interaction network was built. A PERL script was used to
extract identifiers of transcripts that showed any level of expression in the prostate gland, the
identifiers were then converted to HUGO gene symbols. There were a total of 608 confirmed
proteins identified that are reported targets of miRNAs dysregulated in the prostate. These were
obtained by combining the comprehensive list of validated miRNA/target interactions and the list
of transcripts expressed in the prostate.
Using Cytoscape 2.8 along with the Agilent literature search (v2.76) tool, two
literature mined prostate protein-protein interaction networks were inferred 51, 52. For the first
network, each protein in the list of 608 known prostate cancer miRNA target proteins was used
as a search term in the Agilent literature search tool and the search was controlled to limited
interactions to Homo sapiens with a maximum of 10 hits per search string/search engine. The
second, random network, was built in the same manner using 608 randomly chosen proteins
expressed in the prostate gland according to the Unigene database, disregarding known miRNA
status50. Visualization was accomplished using Cytoscape and topological network descriptors
were estimated using CentiScaPe 53.
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The random network built was shuffled 50,000 times using a degree preserving edge
shuffle random network plugin developed by engineers at Syracuse University and implemented
in Cytoscape. The plugin was downloaded
(http://sites.google.com/site/randomnetworkplugin/Home) as a .jar file and installed in the
Cytoscape package.
Statistical analysis of the Networks:
Differences in network distributions were evaluated using an Analysis of Variance test
(ANOVA) with significance set at probability <= 0.05. All statistical analyses were performed
using JMP 8.0 (Statistical Analysis Software Cary, NC). The distribution of node degree for the
prostate miRNA targeted network and the random network were created using the R Project for
Statistical Computing (http://www.r-project.org/).
Network Findings:
In networks analysis, node degree can be used to surmise the proteins contribution to the
stability of the network/cell. Node degree represents the maximum interaction potential of a
protein. A random protein-protein interaction network of proteins was compared to the results
obtained from the miRNA/proven target network and determine the likelihood that the
interaction would have been seen due to chance alone. Table 3-1 shows the node degree
distribution differences between the random network of proteins expressed in the prostate
compared to the miRNA/proven target network of proteins 54. The analysis shows that there is an
enrichment of more highly connected nodes in the miRNA/proven target network than the
network of randomly chosen proteins expressed in the prostate. The random network had an
average node degree of 5 opposed to the miRNA/target networks average node degree of 30.
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Table 3-1: A comparison of node distributions between the random network of proteins
expressed in the prostate and the miRNA/proven target Prostate Cancer network.
Network

Mean Node

Standard

Degree

Deviation

Prostate Cancer miRNA target protein

29.80

Random prostate protein

4.46
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Minimum

Maximum

47.47

1

290

4.24

1

28

The high average node degree implies that miRNAs preferentially target transcripts that
impact a large number of proteins in the cell. The miRNA/proven target network had a maximum
node degree of 290 compared to the random network which had a maximum node degree of 28.
It has been shown that molecules with higher node degrees are more essential to cell growth and
function 55. Perturbations of such highly connected nodes have an increased likelihood of
negatively impacting the stability of the network/cell 46, leading to a variety of diseases such as
cancer 56.
The 608 proteins proven to interact with miRNAs dysregulated in the prostate were
ranked based on their node degree. ERBB2 and ERBB3, both members of the epidermal growth
factor receptor (EGFR) family, were found to be differentially expressed at a statistically
significant level across P69, M12, and M12+miR17-3p cell lines in our proteomics analysis.
Table 3-2 depicts the results of the EGFR protein family represented in the protein-protein
interaction network of proven target/miRNA interactions 54. The EGFR family was found to be
the 6th highest ranked node in our miRNA target network. The higher node degree infers the
importance of this protein family to the stability of the cell/network.
Perturbation of the EGFR family within the cell, potentially by a miRNA, could prove
detrimental to the stability and health of the cell. ErbB2 and ErbB3 show a significant increase in
expression between the non-tumorigenic P69 cell line and the highly tumorigenic, highly
metastatic M12 subline, as well as a high node degree of 248 in our miRNA/target network.
From these results, we believe that ErbB2 and ErbB3 have the potential to play a key role in the
development of prostate cancer. However, the identification of the cause and consequences of
the dysregulation of ErbB2 and ErbB3 is necessary to ultimately prove their role in disease.
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Table 3-2: Protein node connectivity results for EGFR.
Protein

Node Degree

Function

Known miRNAs

EGFR

248

Cell proliferation

hsa-miR-7, hsa-miR125b, hsa-miR-125a,
hsa-miR-331-3p, hsamiR-548d-3p, miRhsa-559, hsa-miR-205
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Chapter 4: Identification of possible miRNA/ErbB2 or ErbB3 interactions.

Screening of the miRnome:
qRT-PCR based microarrays have been developed to produce a high-throughput method
of screening miRNA expression levels of all currently known miRNAs in order to identify key
players in different diseases. Exiqon has developed the miRCURY LNA microRNA Arrays
(catalog # 203607, miRNA human panel 1 and 2 V2.M) for screening of the miRnome
(microRNA transcriptome) using two 384 well plates. Total RNA was extracted using the
miRVana miRNA Isolation Kit from Invitrogen and 50ng of RNA from each cell type was
converted to cDNA using the Exiqon miRCURY LNA Universal RT miRNA PCR kit. The ABI
7900-HT Fast Real-Time PCR System from Applied Biosystems (ABI) was used to amplify and
quantify the expression of 700 known miRNAs using recommended settings (95◦ C for 10
minutes, followed by 40 cycles of 95◦ for 10 seconds and 60◦C for 1 minute).
Utilizing GenEx software from Exiqon, Interplate calibration was performed to minimize
interplate variation. The cycle threshold (CT) for each microRNA was then normalized to the
global mean of the array plate (CT- mean CT). Undetectable expression levels were set greater
than the highest normalized CT value observed for that particular cell line. The P69 cell line
normalized expression value was used as the calibrator. Table 4-1 shows the miRNA that was the
most differentially expressed in our prostate cancer progression model. Achieving a fold change
of this magnitude is possible when the expression level of miR125b is very high in one cell line
(P69) and very low in the comparison cell line (M12). miR125b was proven to target ERBB2
and ERBB3 in breast cancer and CASP6, CASP7 and BAK1 in prostate cancer. Single miR
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Table 4-1: Results of the most differentially expressed miRNA in our miR screen.
miRNA

P69

miR125b

9055X ↓

M12

Proven Targets

Cancer

ERBB2, ERBB3
CASP7, CASP6,BAK1
(50+ total)

Breast
Prostate
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analysis is required to confirm the significance of miR125b dysregulation in our prostate
progression model.
Single miR analysis of miR125b:
Single miR analysis of miR125b expression in our prostate cancer progression model was
performed to verify the results of the Exiqon miR screen. Total RNA was extracted as previously
described in the above section. The TaqMan microRNA Assay Kit (Kit # 000449) from ABI was
used to convert 20ng of RNA from P69 and M12 cells to cDNA, and subsequently analyzed in
triplicate by qRT-PCR. TaqMan probes of RNU48 and miR125b were used in the qRT-PCR
reaction using the ABI 7300 Real-Time PCR system with recommended settings (95◦ C for 10
minutes, followed by 40 cycles of 98◦ for 15 seconds and 60◦C for 1 minute). Expression mean
values were normalized to RNU48 and the P69 cell line was used as the calibrator. Figure 4-1
depicts the relative level of miR125b expression in the M12 cell line compared to the P69 cell
line. A 19.7-fold decrease in miR125b expression was observed from the P69 cell line to the
M12 cell line.
To verify the dysregulation of miR125b in human prostate tissue, single miR analysis of
miR125b expression in benign, stroma, prostatic intraepithelial neoplasia (PIN), benign prostatic
hyperplasia (BPH) and tumor cells was performed. The patient sample was obtained from the
Virginia Commonwealth University Anatomic Pathology Tissue Depository with approved IRB
protocol. The protocol for laser-capture microdissection (LCM) of formalin-fixed paraffinembedded (FFPE) patient samples was followed as previously described by Zhang et al 31. Total
RNA was extracted from benign, stroma, PIN, BPH and tumor tissue using the PicoPure RNA
extraction kit from Life Technologies. RNA quantity and integrity were assessed using the

41

Figure 4-1: The relative level of miR125b expression in the M12 cell line compared to P69.
Total RNA was extracted from M12 and P69 cell pellets, 20ng of each RNA extract was
converted to cDNA and qRT-PCR was performed (in triplicate). Expression level means were
normalized to RNU48 and the P69 normalized value was used as the calibrator. Standard
deviation within each sample is shown.
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Figure 4-1: The relative level of miR125b expression in the M12 cell line compared to P69.
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Agilent Bioanalyzer. cDNA conversion and qRT-PCR was performed in triplicate using the
TaqMan assay as previously described. The mean expression values of each sample were
normalized to RNU48 and the benign normalized expression value was used to calibrate all
samples.
Figure 4-2 depicts the relative level of miR125b expression in stroma, PIN, BPH and
tumor tissue compared to benign tissue expression. A 1-fold increase in miR125b expression was
observed from benign to stroma tissue. A 2.75-fold decrease in expression was observed from
benign to PIN tissue with a 2.82-fold decrease from benign to BPH tissue. A substantial 2452fold decrease in expression was observed from benign to tumor tissue.
Although only one individual human sample was tested, the result of the single miR
analysis of miR125b expression in human tissue was consistent with the single miR data and
miR screen analysis of our prostate cancer progression model. miR125b expression was
significantly lower in the highly metastatic, highly tumorigenic M12 cell line within both the
miR screen and individual miR analysis compared to the non-tumorigenic P69 cell line. Also,
miR125b expression was significantly lower in human tumor tissue compared to benign tissue.
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Figure 4-2: The relative level of miR125b expression in stroma, PIN, BPH and tumor tissue
compared to benign tissue of one individual human prostate sample.
LCM of FFPE tissue was performed. Total RNA was extracted and was converted to cDNA.
qRT-PCR was performed and the expression means were normalized to RNU48. Expression
values of all tissues were calibrated to normalized benign tissue expression. Standard deviation
within each sample is shown.
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Figure 4-2: The relative level of miR125b expression in stroma, PIN, BPH and tumor tissue
compared to benign tissue of one individual human prostate sample.
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The potential for miR125 to target ErbB2 or ErbB3:
Our computational networks approach to identify key proteins that are influenced by
miRNAs dysregulated in prostate cancer suggested the ErbB family of proteins. These proteins
are highly connected nodes in the prostate cancer network suggesting that they are key players in
the development/progression of prostate cancer. Additionally, our proteomics analysis of the
prostate cancer progression model showed that ErbB2 and ErbB3 are significantly dysregulated
between P69 -> M12.Overall the results from analyzing the miRnome of our prostate cancer
progression model, verified by single miRNA analysis, identified miR125b as being the most
differentially expressed tumor suppressing miRNA in our cell lines. Scott et al proposed that
miR-125b binds directly to position 19-44 within the 3’ UTR of ErbB2 (5’GCAGAAGCCCUGAUGUGUCCUCAGGGA-3’) and position 8-26 of ErbB3 (5’UCCCUGUGGCACUCAGGGA-3’) controlling metastatic potential of breast cancer cells 20.
Based on the reported results, it is reasonable to postulate that miR125b could be directly
targeting ErbB2 and ErbB3 in prostate cancer via the binding sites described above.
Computational analysis of ErbB2 and ErbB3 3’UTRs and miR125b:
The 3’UTR sequences for ErbB2 and ErbB3 were obtained from the National Center for
Biotechnology Information (NCBI) and the sequence for miR125b was obtained from miRBase
. The miR125b sequence and 3’UTR sequences of ErbB2 and ErbB3 were submitted to

27, 57, 58

RNAhybrid, a miRNA/RNA minimum free energy structural hybridization prediction tool, using
the default settings 59. Figure 4-1 depicts the predicted structural interaction of miR125b and the
3’UTRs of ErbB2/ErbB3. Many of the proven miRNA binding sites have perfect seed region
(bases 2-8) Watson-Crick binding, adequate minimum free energy of formation (deltaG < -20.0
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Figure 4-1: Previously described miR125b coupling with the 3’UTR of ErbB2 or ErbB3.
The sequences of the complete 3’UTR of (A) ErbB2/ (B) ErbB3 and the sequence of miR-125b
were compared using RNAhybrid to predict potential interactions of miR-125b (green) with the
3’ UTRs of ErbB2/ ErbB3 (red) 59. Potential structures and the minimum free energy of
formation of the binding sites proposed by Scott et al are shown.
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Figure 4-1: Previously described miR125b coupling with the ErbB2 or ErbB3 3’UTRs.

A.

B.
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kcal/mol), and some degree of 3’ stabilization. The structure of the proposed binding sites for
both proposed miRNAs adhere to previously observed characteristics and thus it is reasonable to
suspect that these interactions would occur in vivo.
Mutation of seed region binding in the 3’UTRs of ErbB2 and ErbB3 is required to
determine if these are true miRNA/target interactions within the prostate gland and if these
interactions may be contributing to the development of prostate cancer. In order to evaluate
potential binding, a reporter construct containing mutations of three bases (2-4, GGG to TTT)
within the 3’UTRregion of ErbB2 and ErbB3 proposed to be under miR-125b regulation was
constructed. To confirm that the mutations decrease the likelihood of microRNA regulation, the
mutated sequence was evaluated using RNAhybrid. Since complete seed region binding does not
exist, there is a poor minimum free energy. Most likely neither the mutant ErbB2 3’UTR or the
mutant ErbB3 3’UTR are likely to be under the control of miR-125b regulation (Figure 4-2).
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Figure 4-2: miR125b coupling with the mutated ErbB2 and ErbB3 3’UTRs.
The sequences of the proposed mutant 3’ UTR of (A)ErbB2 / (B)ErbB3 and the sequence of
miR-125b were compared using RNAhybrid to predict potential interactions of miR-125b
(green) 59. Potential structures and the minimum free energy of formation of the mutant binding
sites are shown.
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Figure 4-2: miR125b coupling with the mutated ErbB2 and ErbB3 3’UTRs.

A.

B.
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ErbB2 and ErbB3 oligonucleotides:
Eight custom oligonucleotides were synthesized (Invitrogen), including both forward and
reverse strands of the wild type (wt) and mutant (mut) ErbB2 as well as ErbB3 3’UTR segments.
Each annealed oligonucleotide pair on the 5’-end was synthesized with a blunt DraI restriction
enzyme recognition sequence followed by an internal full NotI restriction enzyme recognition
sequence, the requisite ErbB2 or ErbB3 3’UTR sequence and a 3’-end sticky XbaI restriction
enzyme recognition sequence for proper insertion into the multiple cloning site (digested with
DraI/XbaI) of the pmiRGlo vector (Promega). Figure 4-3 displays the ErbB2 and ErbB3 wt and
mut oligonucleotides synthesized for insertion into the pmiRGlo vector (Promega). A three base
pair mutation within the miR125b seed binding region (bases 2-4) was achieved by changing
GGG to TTT.
The lyophilized oligos were re-suspended in TE buffer to a final concentration of 200uM
and stored at -20◦C. Oligonucleotides were annealed in a 20ul reaction containing 5ul each of a
forward and reverse strand, 2ul of 10X Oligo annealing buffer (100mM Tris-HCL, 10mM
EDTA, 1M NaCl) and 8ul of DNAse/RNAse free water. Annealing was accomplished by
incubation at 95◦C for 4 minutes on a heat block, followed by gradual cooling at room
temperature for one hour. Annealed oligos were stored at -20◦C.
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Figure 4-3: ErbB2 and ErbB3 wild type and mutant synthesized oligonucleotides:
Each annealed oligonucleotide pair on the 5’-end was synthesized with a blunt DraI restriction
enzyme recognition sequence followed by an internal full NotI restriction enzyme recognition
sequence, the requisite ErbB2 or ErbB3 3’UTR sequence and a 3’-end sticky XbaI restriction
enzyme recognition sequence for proper insertion into the multiple cloning site (digested with
DraI/XbaI) of the pmiRGlo vector (Promega). A three base pair mutation within the miR125b
seed binding region (bases 2-4) was achieved by changing GGG to TTT.
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Figure 4-3: ErbB2 and ErbB3 wild type and mutant synthesized oligonucleotides:
ErbB2wt:
5’– AAACTAGCGGCCGCAGGCCAAGTCCGCAGAAGCCCTGATGTGTCCTCAGGGAGCAGGGAAGGT
-3’
3’– TTTGATCGCCGGCGTCCGGTTCAGGCGTCTTCGGGACTACACAGCAGTCCCTCGTCCCTTCCAGATC -5’

ErbB2mut:
5’– AAACTAGCGGCCGCAGGCCAAGTCCGCAGAAGCCCTGATGTGTCCTCATTTAGCAGGGAAGGT
-3’
3’– TTTGATCGCCGGCGTCCGGTTCAGGCGTCTTCGGGACTACACAGCAGTAAATCGTCCCTTCCAGATC -5’

ErbB3wt:
5’- AAACTAGCGGCCGCCTCCTGCTCCCTGTGGCACTCAGGGATTAGGGAATGGATAAGAGTGCCT
-3’
3’- TTTGATCGCCGGCGGAGGACGAGGGACACCGTGAGTCCCTAATCCCTTACCTATTCTCACGGAGATC -5’

ErbB3mut:
5’- AAACTAGCGGCCGCCTCCTGCTCCCTGTGGCACTCATTTATTAGGGAATGGATAAGAGTGCCT
-3’
3’- TTTGATCGCCGGCGGAGGACGAGGGACACCGTGAGTAAATAATCCCTTACCTATTCTCACGGAGATC -5’
DraI-Restriction site
NotI-Blunt end
XbaI-Sticky end
miR125b target site
miR125b target mutation
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ErbB2 and ErbB3 plasmid cloning:
The pmiRGlo vector (2µg) was digested with 2-units of DraI (New England Biolabs NEB), 2 units of XbaI (NEB) in NEB buffer 4 with 1xBovine Serum Albumin (‘BSA’ from
NEB) and brought up to a 20µl reaction volume with DNAse/RNAse free water. The sample was
incubated in a water bath at 37◦C for 1 hour and 30 minutes. Heat inactivation of the enzymes
was achieved by heating the sample for 20 minutes on a heat block at 65◦C. The ligation reaction
was set up so that there was an 8:1 insert (400ng) to vector (50ng) ratio. In a reaction volume of
20µl, the mixture contained 1xT4 DNA Ligase buffer (NEB) and 2-units of T4 DNA ligase
(NEB). The sample was incubated at 25◦C for 1 hour.
Competent DH5-alpha E. coli cells (50 l) were transformed with the ligation mixture
(10 l). Transformation was accomplished by incubation on ice for 30 minutes, followed by a 45
second heat-shock at 42◦C and then 2 minutes on ice. Pre-warmed (37◦C) Luria Broth (LB)
media (950µl) was added to each mixture and incubated for 1 hour (37◦C with 225 rpm). Colony
selection was accomplished by plating 200ul and 50ul of each transformation onto
LB+Ampicillin (0.1µg/ml) plates and incubated overnight at 37◦C. Single colonies from each
transformation were selected and used to inoculate 250ml of LB+Ampicillin media (0.1µg/ml)
per sample and incubated overnight (37◦C with 225 rpm). Maxipreps of the inoculates were
performed using the PowerPrep Plasmid Purification Kit from Origene with integrated pre-filters
following the manufacturer’s protocol. The DNA sequence of the various 3’UTR inserts was
verified by the Nucleic Acids Research Facilities (NARF) at Virginia Commonwealth
University.
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Cell line Transfections with ErbB2 and ErbB3 wild type and mutated 3’UTRs:
P69 and M12+miR17-3p cell lines were transfected with the entire 3’UTR of ErbB2 and
ErbB3 inserted into the XbaI restriction site of the PGL3 promoter vector (PGL3 vector +3'UTR
of pErbB2 or pErbB3) fused 3’- to the firefly luciferase gene. The constructs were provided to us
by Dr. Christopher C. Benz at the Buck Institute for Age Research, Novato, CA 20. In addition,
the P69 cell line was transfected either with the wild type or mutated 3’UTR constructs of ErbB2
and ErbB3 inserted into the pmiRGlo vector as previously described. Prior to transfection,
200,000 actively growing cells were plated per well in triplicate on a 6 well plate and cultured at
37◦C for 24 hours. Cells were cultured and passed at least twice before transfection and counted
using a Beckman-Coulter particle counter.
Transfection was accomplished with TransIT transfection reagent from Mirus (2µg
TransIT/ng DNA) and incubated at room temperature for 5 minutes with serum free RPMI 1640
media plus L-glutamine (Sigma-Aldrich). For the PGL3 constructs, purified plasmid (1µg) either
PGL3 vector with no insert or PGL3 vector plus pErbB2 or pErbB3 3’UTRs was complexed
with transfection reagent plus the renilla luciferase control reporter vector (15ng). The optimal
ratios of PGL3 and renilla plasmid were previously determined31. For the pmiRGlo constructs,
purified plasmid (250ng) was complexed with transfection reagent creating these test samples,
pmiRGlo with no insert or pmiRGlo with pErbB2wt, pErbB2mut, pErbB3wt or pErbB3mut
3’UTRs. Each sample was incubated for 30 minutes at room temperature. Fresh media as
previously described for each cell type was added to each well and the TransIT/RPMI/plasmid
mixture was dripped over each well shaking gently side to side. The amount of DNA utilized for
the pmiRGlo vector and incubation time were determined empirically and found to produce the
most favorable results.
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After 48 hours of incubation at 37◦C, the cells were lysed for 30 minutes directly on the
plate with passive lysis buffer (Promega). Cell lysates were stored at -80◦C for ~24 hours.
Reporter activity was measured using the Promega Dual Luceriferase Assay Kit. Cell lysates and
reagents were warmed to room temperature per manufacturer’s instructions. Reporter activity
(firefly luciferase) was quantified using 30µl of the cell lysate plus 30µl of the luciferase assay
reagent II (LAR II) and measured with a Glowmax Luminometer. Control reporter activity
(Renilla luciferase) was assayed in the same manner after the addition of 30µl of the Stop &
Glow reagent. Reporter activity is presented as a ratio of firefly luciferase to renilla luciferase
activity.
Findings of the ErbB2 and ErbB3 Transfections in P69 cells:
The P69 cell lines were first transfected with the PGL3 plasmids containing the entire
ErbB2 or ErbB3 3’UTR sequence to determine if an actual affect was detected within our
prostate cancer progression model (Figure 4-4). The non-metastatic P69 cell line was chosen
since this cell type exhibits a higher level of miR17-3p expression compared to the M12 cell line.
A 2.8-fold or 2.4-fold decrease in expression was observed when comparing the mean expression
of the PGL3 empty vector to the mean expression of the pErbB2 or pErbB3 3’UTR containing
vectors respectively. Based on these results, translation of both the ErbB2 and ErbB3 mRNAs
are being influenced by some non-coding RNA molecule that is binding within the respective
3’UTRs.
The P69 cell line was also transfected with the pmiRGlo vector containing ErbB2wt,
ErbB3mut, ErbB3wt and ErbB3mut 3’UTR sequence to determine if miR125b is directly
targeting ErbB2 or ErbB3 mRNAs within our prostate cancer progression model. Figure 4-5
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Figure 4-4: The 3’UTRs of pErbB2 and pErbB3 repress luciferase reporter activity.
P69 cells (200,000 cells per well) were transfected in triplicate with 1µg of PGL3 empty vector,
or vector containing the entire pErbB2 or pErbB3 3'UTR sequences. Luciferase activity was
measured 48 hrs later and expressed as the ratio of firefly to renilla. Standard deviation within
each sample is shown.
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Figure 4-4: The 3’UTRs of pErbB2 and pErbB3 repress luciferase reporter activity.

4.5

P69

Ratio of Fire Fly to Renilla

4
3.5
3
2.5
2
1.5
1
0.5
0
PGL3

pErbB2

60

pErbB3

Figure 4-5: miR125b does not directly affect luciferase expression of ErbB2 and ErbB3 wt
and mut vectors in the P69 cell line.
P69 cells (200,000 cells per well) were transfected in triplicate with 250ng of pmiRGlo empty
vector, pErbB2wt, pErbB2mut, pErbB3wt or pErbB3mut plasmids. Luciferase activity was
measured 48 hrs later and expressed as the ratio of firefly to renilla. Standard deviation within
each sample is shown.
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Figure 4-5: miR125b does not directly affect luciferase expression of ErbB2 and ErbB3 wt
and mut vectors in the P69 cell line.
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depicts the results from the transfections of pmiRGlo, pErbB2wt, pErbB2mut, pErbB3wt and
pErbB3mut in the P69 cell line. The P69 cell line was chosen because it has the highest
endogenous expression of miR125b in our prostate cancer progression model. If there was a
direct interaction between miR125b and the ErbB2 and ErbB3 3’UTRs we would have expected
a decrease in luciferase expression between pmiRGlo and the pErbB2wt or pErbB3wt. Based on
these results, no direct binding within the 3’UTRs of ErbB2 and ErbB3 at the miR125b proposed
binding sites identified by Scott et al could be detected by this assay method 20.
The potential for miR17-3p to target ErbB2 or ErbB3:
In addition to our computational networks identification of the ErbB family of proteins as
key players in the development/progression of prostate cancer, our proteomics analysis of the
prostate cancer progression model showed that ErbB2 and ErbB3 are significantly dysregulated
between M12→M12+miR-17-3p. Based on these results, we propose miR17-3p may directly
bind to the 3’UTRs of either or both ErbB2 and ErbB3, which would identify a new
miRNA/target interaction.
Computational analysis of ErbB2 and ErbB3 3’UTRs and miR17-3p:
The sequence for miR17-3p was obtained from miRBase

57, 58

.The miR17-3p sequence

and 3’UTR sequences of ErbB2 and ErbB3 were submitted to RNAhybrid, a miRNA/RNA
minimum free energy structural hybridization prediction tool, using the default settings 59. Figure
4-6 depicts the predicted structural interaction of miR17-3p and the 3’ UTRs of ErbB2/ErbB3.
Many of the proven miRNA binding sites have near perfect seed region (bases 2-8) WatsonCrick binding, adequate minimum free energy of formation (deltaG < -20.0 kcal/mol), and some
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Figure 4-6: Predicted miR17-3p coupling with the 3’UTR of ErbB2 or ErbB3.
The sequences of the complete 3’ UTR of (A) ErbB2 /(B) ErbB3 and the sequence of miR17-3p
were compared using RNAhybrid to predict potential interactions of miR17-3p (green) with the
3’ UTRs of ErbB2/ ErbB3 (red) 59.
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Figure 4-6: Predicted miR17-3p coupling with the ErbB2 or ErbB3 3’UTRs.

A.

B.
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degree of 3’ stabilization. The structure of the proposed binding sites for both proposed miRNAs
adhere to previously observed characteristics and thus it is reasonable to suspect that these
interactions would occur in vivo.
Findings of the ErbB2 and ErbB3 Transfections in M12+miR17-3p cells:
The M12+miR-17-3p cell line was transfected with the pErbB2 and pErbB3 plasmids to
elucidate any potential miR17-3p interaction between the ErbB2 and ErbB3 3’UTRs in prostate
cancer. Figure 4-7 depicts the results from the transfections of PGL3/Renilla, pErbB2/Renilla
and pErbB3/Renilla in the M12+miR-17-3p cell line. If there was a direct interaction between
miR17-3p and the ErbB2 and ErbB3 3’UTRs we would have expected a decrease in the ratio of
firefly to renilla expression between PGL3 and the pErbBs. Based on these results, it was
concluded that miR17-3p may be indirectly affecting the translation of the ErbB2 and ErbB3
mRNAs, but no direct binding within the 3'UTRs of pErbB2 or pErbB3 could be detected by this
assay method.
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Figure 4-7: miR17-3p does not directly affect luciferase expression of pErBb2 or pErbB3 in
the M12+miR17-3p cell line.
M12+miR17-3p cells (200,000 cells per well) were transfected in triplicate with 1µg of PGL3
empty vector, pErbB2 or pErbB3 plasmids. Luciferase activity was measured 48 hrs later and
expressed as the ratio of firefly to renilla. Standard deviation within each sample is shown.
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Figure 4-7: miR17-3p does not directly affect luciferase expression of pErBb2 or pErbB3 in
the M12+miR17-3p cell line.
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Discussion:
We took a multifaceted approach, combining a computationally built protein-protein
interaction network of proteins experimentally proven to be targeted by miRNAs with high
throughput proteomics to identify key protein targets in prostate cancer. This analysis coupled
with screening the miRnome enhanced our identification of miRNAs that are dysregulated in
prostate cancer. To our knowledge, this study is the first to combine all three approaches to
elucidate new miRNAs and targets contributing to prostate cancer progression.
Our computational networks approach identified the ErbB family of proteins as highly
connected nodes and therefore key players in the prostate cancer network. Additionally,
proteomic analysis of our prostate cancer progression model suggested ErbB2 and ErbB3 as
significantly dysregulated proteins. Several miRNA array screens substantiated by single miR
analysis of the P69 and M12 related sublines produced miR125b as being highly differentially
expressed. Previously, it was suggested that miR125b targets ErbB2 and ErbB3 and functions as
a tumor suppressor in breast cancer 20. Our results suggest a similar function for miR125b in
prostate cancer where the differential expression of miR125b could be responsible at least in part
for the dysregulation of the ErbBs.
Reporter gene assays were conducted to further explore the relationship between
miR125b and the ErbBs. Fusion of the entire 3'UTR of either ErbB2 or ErbB3 to the luciferase
reporter gene resulted in a 2.8-fold and 2.4-fold decrease (respectively) in activity in p69 cells
compared to the parental PGL3 vector. However, inclusion of the miR125b/ErbB2 or ErbB3
binding sites as proposed in the Scott et al paper did not produce the luciferase expression
profiles expected of a miRNA/target interaction 20. Several theories could explain the
inconsistency between our results and those previously published. Foremost is the fact that the
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binding site identified in the Scott et al paper was not examined by mutagenesis and therefore
may be incorrect. Recently, the National Institutes of Health published a manuscript describing
experimental methods to most accurately validate miRNA targets 60. Here, it was concluded that
insertion of the entire 3’UTR of the target into the expression vector is necessary to prevent
unintentional structural changes that may hinder miRNA/target binding. Thus, transfection of a
plasmid containing the entire 3’UTR fused to a reporter compared to selected base pair mutations
of just that region targeted by the miRNA seed within the entire 3’UTR is proposed to be a more
accurate option to prove a miRNA/target interaction. In the case of the Scott et al paper 20, failure
to specifically mutate just those bases proposed to be targeted by the seed region of miR125b
fails to prove a specific miR125b interaction, yet numerous papers in the literature refer to this
paper as proof of ErbB2 or ErbB3/miR125b interaction. However, many researchers have used
this approach to presumably validate miRNA/mRNA interaction. We found that fusion of just
the target region or a 3 base pair mutation thereof failed to produce any change in reporter
activity. In agreement with NIH guidelines this could be due to the inability to correctly
duplicate a structurally active target region 60. Alternatively, it may be due to the fact that we
mutated only 3 of the bases within the target region. It may be necessary to mutate all 6 bases
within miR125b target site before ruling out the importance of this region as a functional
miR125b binding site.
The aforementioned NIH guidelines go on to state that over-expression of the miRNA to
increase miRNA copy availability is not necessary or "ideal" to validate miRNA/mRNA
interaction because this could lead to non-physiological interactions 60. When Scott et al
performed their analysis, they infected their cells with a retrovius expressing a mature miR125b
sequence to attain high level expression 20. From the NIH guidelines this might not be the most
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relevant protocol. In our case we used P69 cells which naturally express miR125b at a level
significantly higher than the M12 cell line. Thus, we were not forced to artificially manipulate
miR125b expression levels but rather worked within the confines of endogenous expression
levels.
Lastly, deletion of ErbB2 (44 bp) or ErbB3's (22 bp) proposed miR125 binding site in the
Scott et al paper, produced at best only a 1.4-fold decrease in luciferase activity compared to the
wild type vector 20. In our case inclusion of the entire 3'UTRs generated a significantly greater
decrease, 2.4- or 2.8-fold, compared to the PGL3 vector with no insert. Our results suggest
additional mechanisms of ErbB regulation above those included by the aforementioned deletions.
The most obvious explanation here is that multiple miR125b binding sites might reside within
the 3'UTRs of ErbB2 or ErbB3, which in a combinatorial fashion control ErbB expression. The
contribution of only one of these sites, and maybe not the most functional site, was studied by
Scoot et al. In fact, further computational examination of the ErbB2 and ErbB3 3’UTRs using
RNAhybrid, identified a better miR125b binding site to ErB259. Figure 4-8 depicts a potential
structure formed with a lower minimum free energy of conformation (-24.4kcal/mol) than that
exhibited by the Scott region (-21.9 kcal/mol). The structure of the proposed binding site adheres
to previously observed characteristics and thus it is reasonable to suspect that this interaction
would occur in vivo. Future experiments including mutation of these relevant seed region target
bases will be required to determine if this is a functional miR125b binding site.
Last of all, it is possible that miRNAs in addition to or together with miR125b is
targeting the ErbBs. Previously, single miRNA analysis showed that miR17-3p is differentially
expressed in our prostate progression model. Additional experiments showed that miR17-3p can
act as a tumor suppressor in vitro and in vivo 31. Proteomic data showed that overexpressing
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Figure 4-8: A better predicted miR125b binding site within the ErbB2 3’UTR.
RNAhybrid predicted structure of binding between miR125b and the 3’ UTR of ErbB2 59.
miR125b is represented in green and the 3’UTR of ErbB2 is represented in red.
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Figure 4-8: Predicted best miR125b coupling with the ErbB2 3’UTR.
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miR-17-3p in the M12 cell line resulted in a decrease in expression of ErbB2 and ErbB3
suggesting additional regulation by miR17-3p. However, luciferase assays did not confirm a
direct interaction between miR17-3p binding and a predicted binding site within ErbB's 3'UTR.
This suggests that miR17-3p is either binding to another unknown site or is affecting the
expression of a secondary molecule which in turn affects ErbB2 or ErbB3 expression. Although
miR17-3p's direct interaction on the ErbBs could not be confirmed as yet, our miR screen
analysis does suggest many miRs that are differentially expressed in the various cell lines of our
cancer progression model. Thus, there is a strong possibility that additional miRNAs targeting
the ErbBs will be uncovered in the continuation of these studies.
In summary the compilation of results from a computational networks approach,
proteomics and miRnome analysis has suggested miR125b and the ErbBs as relevant players in
prostate cancer progression. Potentially new miRNAs and targets have thus been identified,
which warrant further study. Prostate cancer is the second most common cancer affecting men
today and the second leading cause of cancer deaths in American men. Therefore, there is a
strong need for accurate biomarkers and successful therapeutic treatments in which identification
of miRNAs and proteins that contribute to prostate cancer progression could prove invaluable to
combating this disease.
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